Aristides Capital LLC Makes New Investment in Chemed Corporation $CHE

Aristides Capital LLC acquired a new stake in shares of Chemed Corporation (NYSE:CHE) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 437 shares of the company’s stock, valued at approximately $213,000.

Other large investors have also made changes to their positions in the company. Creekmur Asset Management LLC acquired a new position in Chemed during the second quarter valued at $28,000. SVB Wealth LLC acquired a new stake in Chemed during the 1st quarter worth about $30,000. WPG Advisers LLC purchased a new position in shares of Chemed during the 1st quarter valued at about $32,000. Parkside Financial Bank & Trust lifted its holdings in shares of Chemed by 86.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after buying an additional 44 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after buying an additional 76 shares during the period. 95.85% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Monday, November 24th. The stock was sold at an average price of $437.55, for a total value of $875,100.00. Following the sale, the chief executive officer owned 94,197 shares in the company, valued at $41,215,897.35. The trade was a 2.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Patrick P. Grace sold 150 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total value of $69,508.50. Following the transaction, the director owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. This represents a 4.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 5,150 shares of company stock valued at $2,328,449. 3.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Royal Bank Of Canada dropped their target price on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Bank of America lowered their price objective on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research report on Wednesday, September 10th. Oppenheimer cut their target price on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Chemed currently has an average rating of “Moderate Buy” and an average price target of $574.25.

Chemed Price Performance

Shares of Chemed stock opened at $441.09 on Friday. The stock’s 50 day simple moving average is $440.81 and its 200-day simple moving average is $475.50. The stock has a market cap of $6.25 billion, a P/E ratio of 23.33, a P/E/G ratio of 2.69 and a beta of 0.43. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The company had revenue of $624.90 million for the quarter, compared to analysts’ expectations of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, research analysts expect that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Monday, November 17th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s dividend payout ratio is currently 12.69%.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.